Theravance Biopharma, Inc. (TBPH)

Theravance Biopharma Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Nov 4, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	402	560	755	814	1,137	1,470
Market Cap Growth	-31.06%	-25.82%	-7.35%	-28.37%	-22.63%	3.64%
Enterprise Value	352	477	320	1,269	1,398	1,620
Last Close Price	8.21	11.24	11.22	11.05	17.77	25.89
PE Ratio	-	-11.26	0.95	-3.84	-3.98	-6.09
PS Ratio	6.57	9.75	14.70	14.72	15.82	20.02
PB Ratio	2.07	2.63	1.71	-2.41	-3.74	-6.57
P/FCF Ratio	-42.95	-18.98	-4.02	-3.85	-4.42	-6.09
P/OCF Ratio	-46.99	-20.73	-4.04	-3.92	-4.54	-6.17
EV/Sales Ratio	5.68	8.30	6.23	22.95	19.46	22.07
EV/EBITDA Ratio	-9.20	-8.96	-4.20	-5.45	-4.76	-6.51
EV/EBIT Ratio	-9.25	-8.94	-4.04	-5.34	-4.70	-6.43
EV/FCF Ratio	-37.53	-16.16	-1.70	-6.01	-5.44	-6.71
Debt / Equity Ratio	0.24	0.23	0.12	-1.98	-2.23	-2.28
Debt / FCF Ratio	-4.86	-1.67	-0.28	-3.17	-2.63	-2.12
Asset Turnover	0.15	0.12	0.10	0.13	0.16	0.15
Quick Ratio	4.81	4.84	11.99	3.20	2.93	2.97
Current Ratio	5.20	5.39	12.31	4.26	3.18	3.03
Return on Equity (ROE)	-19.27%	-16.86%	-179.84%	-	-	-
Return on Assets (ROA)	-6.02%	-6.73%	-10.07%	-35.20%	-42.38%	-32.49%
Return on Capital (ROIC)	-8.51%	-8.81%	-11.99%	-42.23%	-56.44%	-45.67%
Earnings Yield	-11.37%	-9.86%	115.58%	-24.49%	-24.45%	-16.09%
FCF Yield	-2.39%	-5.27%	-24.86%	-25.94%	-22.61%	-16.42%
Buyback Yield / Dilution	24.30%	24.85%	-5.95%	-11.41%	-12.11%	-3.04%
Total Shareholder Return	24.30%	24.85%	-5.95%	-11.41%	-12.11%	-3.04%

Source: S&P Capital IQ. Standard template. Financial Sources.